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Recent evidence suggests that targeting higher hemoglobin
values with erythropoiesis stimulating agents (ESAs) may lack
mortality benefits and may even result in adverse
cardiovascular complications when used in chronic kidney
disease patients. However, ESAs are frequently reported to
result in improvements in health-related quality of life
(HRQOL). The purpose of this review is to evaluate the
magnitude and nature of ESA-associated improvements in
HRQOL, as well as to understand how to interpret the clinical
significance of HRQOL data. HRQOL findings should be
analyzed not by statistical significance but rather by using
a minimal clinically important difference approach, or,
alternatively, a distribution-based approach (such as Cohen’s
effect size). HRQOL domains that are most improved with
ESAs relate to physical symptoms, vitality, energy, and
performance; domains of social functioning and mental
health show modest improvement, whereas the domains of
emotional functioning and pain show very little
improvement. Additional domains not measured by
commonly used instruments (such as the SF-36) that have
been shown to improve with ESAs include sleep, cognitive
functioning, and sexual functioning. The maximal increase in
HRQOL per incremental increase in hemoglobin appears to
occur in the range of 10–12 g/dl. Beyond this range,
additional normalization of hemoglobin (to 12–14 g/dl)
results in continued (albeit blunted) improvements in
HRQOL.
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Given recent trials demonstrating that complete compared with
partial correction of anemia in chronic kidney disease (CKD)
patients does not appear to reduce the risk of cardiovascular
complications1 and may even contribute to an increased
propensity for adverse complications,2 the benefits of
erythropoiesis-stimulating agents (ESAs) are being debated.
An improvement in health-related quality of life (HRQOL) is
frequently cited as an effect of successful treatment of anemia.
We therefore sought to understand and review the magnitude
and nature of ESA-associated improvements in HRQOL.
The National Kidney Foundation defines anemia as a
hemoglobin (Hb) concentration less than 12.0 g/100 ml in
women and less than 13.5 g/100 ml in men.3 Despite the
availability of recombinant human erythropoietin since 1989,
the treatment of anemia in patients with CKD and cancer
remains an enormous burden to the health care system.4 For
example, the point prevalence of anemia associated with
CKD in the United States is estimated to be four million
people.5
Anemia is associated with cardiovascular complications
such as worsening heart failure, left ventricular hypertrophy,
and angina.6 It has also been associated with functional
impairment, mobility impairment, increased risk of falls, and
diminished HRQOL.7–10 Treatment of anemia using ESAs has
consistently improved HRQOL, as demonstrated by several
meta-analyses.11,12 However, the measurement of HRQOL is
fraught with difficulties, as neither a universal nor a gold
standard instrument has been adopted for the quantification
of this necessarily subjective entity.13 Moreover, when
attempts are made to quantify improvements in HRQOL,
such improvements are often described as mean changes in
the score of a standardized instrument instead of in language
with which clinicians and patients are more familiar. Finally,
in discussing ESA therapy, the cost of improving HRQOL is
often not mentioned, though it is very significant, measured
as billions of dollars.14
Questions that will be addressed in this review include the
following: (1) what are the most commonly used instruments
used in the measurement of HRQOL in CKD patients? (2)
how does one interpret whether an improvement in an
HRQOL score is clinically meaningful? (3) which domains
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and dimensions of HRQOL are most improved by treatment
of anemia? (4) what is the magnitude of such improvements?
and (5) what is the nature of improvements in HRQOL seen
at different levels of Hb correction?
INSTRUMENTS FOR THE MEASUREMENT OF HRQOL
The following is a brief description of some of the more
commonly used measures of HRQOL.
SF-36
The Medical Outcomes Study Short Form-36 (SF-36) is a
self-administered general health survey composed of 36
questions spanning eight physical and mental health domains
(Figure 1).16 Scores for the eight domains (or scales) are
calculated from a subset of the 36 questions that pertain to
that specific domain. For example, the vitality domain is
computed based on the responses to four questions: ‘how
much of the time during the past 4 weeks did you feel (1) full
of pep? (2) tired? (3) worn out? (4) full of energy?’ Responses
range from dichotomous answers to a maximum of six
possible choices, with each choice being numerically coded
and translated into a score, with higher scores indicating
better health status. In addition, two summary measures can
be computed as aggregates from four scales (Figure 1).
SIP
The Sickness Impact Profile (SIP) is a self-administered
behavior-based questionnaire that measures dysfunction
related to illness.17 The complete instrument contains 136
items grouped into 12 domains: sleep and rest, emotional
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Figure 1 | SF-36 items, scales, and summary measures. PCS, physical component summary; MCS, mental component summary. Adapted
from Ware and Gandek.15
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behavior, body care and movement, home management,
mobility, social interaction, ambulation, alertness behavior,
communication, work, eating, and recreation and pastimes.
Multiple domains can be aggregated to give a physical
dimension score and a psychosocial dimension score. An
overall score can also be derived from the combined weighted
scores of all 12 categories. Unlike the SF-36, higher scores on
the SIP indicate greater disability.
LASA
The Linear Analog Self-Assessment (LASA) scale, also known
as the Visual Analog Scale, uses a 100 mm line with
descriptors at each extreme, such as ‘worst possible’ and
‘best possible’ at the left and right ends of the scale,
respectively. Subjects indicate their current state by making a
mark somewhere along the line, which is then measured as a
score in millimeters from the ‘0’ point.13 The LASA
instrument includes 25 items encompassing the domains of
physical functioning, symptoms and side effects, mood,
energy, activity, overall QOL, and social relationships.18
KDQ
The Kidney Disease Questionnaire (KDQ) is specific for
patients with end-stage renal disease and consists of 26 self-
administered questions in five domains (physical symptoms,
fatigue, depression, relationships with others, and frustra-
tion).19 KDQ Part 1 asks patients to select the 6 most
troublesome physical symptoms at baseline from a list of 30,
and those symptoms are then used for that patient
throughout the duration of a study. KDQ Part 2 asks patients
about the remaining four domains. All questions are scored
on a seven-point Likert scale (1¼ severe problem, 7¼ no
problem) and domain scores (also ranging from 1 to 7) are
calculated from a subset of corresponding questions. An
overall score can be calculated as the sum of all KDQ domain
scores.
INTERPRETING THE CLINICAL SIGNIFICANCE OF HRQOL DATA
One of the most important and difficult challenges in
studying HRQOL is translating apparent improvements in
quality of life scores into clinically meaningful terms.20
Because HRQOL scores are measured as continuous
variables, improvements in such scores may be statistically
significant and yet have little clinical relevance.13 To aid
clinicians and researchers in understanding the importance
of changes in HRQOL scores, two tools are used with
increasing frequency: the minimal clinically important
difference (MCID) and the effect size. The MCID is most
often defined as ‘the smallest difference in score in the
domain of interest which patients perceive as beneficial and
which would mandate, in the absence of troublesome side
effects and excessive cost, a change in the patient’s manage-
ment.’21 Some estimates of MCIDs for the four instruments
described above are shown in Table 1. Although these
estimates were not obtained from CKD patients specifically,
Osoba and King28 note a ‘remarkable convergence of results’
in HRQOL assessments among a diverse range of diseases,
including asthma,29 chronic heart and lung disease,21
osteoarthritis,30 and cancer.31 Similarly, Norman et al.32
reviewed a large number of studies and concluded that the
minimum discernable difference that patients can detect is
quite reliable across populations and is approximately equal
to one half of a standard deviation of a given HRQOL
instrument.
MCIDs are usually established by relying on patients’
global ratings of change in their own health. By this
approach, subjects are asked to retrospectively judge whether
a particular aspect of their health has improved, stayed the
same, or worsened, using a single item with several response
options. The degree of change on this single global rating
scale is then related back to the magnitude of change of an
HRQOL instrument to obtain a numerical value denoting the
MCID.28
Norman et al.33 describe multiple problems with this
approach. The reliability (internal consistency) of any scale is
directly related to the number of items on the scale.
Therefore, single global ratings will often have poor reliability
and validity when compared with multi-item HRQOL scales
(although direct evidence for the former is not possible as
internal consistency cannot be computed for single item
scales). If this were not the case, then the shorter single global
rating could simply be substituted for the more complex
HRQOL scale. Another drawback of the above approach is
that retrospective computations of global health scores
depend on the ability of patients to quantify both their
present state and their initial state. They then must perform a
mental subtraction, and yet there is evidence that this
complex judgment of change is psychologically difficult and
imprecise.34,35
An alternative to the MCID approach is the distribution-
based approach, which relates differences in treatment groups
to some measure of variability. The most commonly used
distribution-based approach involves calculating the Cohen’s
standardized effect size, which is simply the mean change
divided by the standard deviation.36 By this method, effect
sizes of 0.2–0.5 are regarded as ‘small’, 0.5–0.8 as ‘moderate’,
and those above 0.8 are considered ‘large’. Effect sizes are
influenced by both the magnitude of effect and by variability
within the sample. Some investigators have suggested that
effect sizes may underestimate clinically important differ-
ences.37 In addition, effect sizes, unlike MCIDs, cannot be
Table 1 | Minimal clinically important difference of various
HRQOL scales
Instrument MCID Reference
SF-36 3–5 Samsa et al.22
SIP 3–5 Damiano et al.;23 Deyo and Centor24
LASA 10–20 Todd and Funk;25 Ander et al.;26 Patrick et al.27
KDQ 0.5 Jaeschke et al.21
HRQOL, health related quality of life; MCID, minimal clinically important difference;
SF-36, Short Form-36; SIP, Sickness Impact Profile; LASA, Linear Analog Self-
Assessment; KDQ, Kidney Disease Questionnaire.
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used to interpret individual-based differences.28 Nonetheless,
distribution-based approaches and effect sizes are often
useful in meta-analyses, in which the findings from multiple
different instruments must be evaluated cumulatively.11
IMPROVEMENTS IN HRQOL WITH TREATMENT OF ANEMIA
Although there is general agreement that correction of
anemia improves HRQOL, the specific domains that are
improved and the magnitude of such improvements are less
well defined. Tables 2a–d show the results of representative
studies reporting ESA-associated improvements in HRQOL
as measured by the SF-36, SIP, LASA, and KDQ, respectively.
Given the differing methodologies used to assess HRQOL
and the different patient population studies, we did not
attempt to perform a meta-analysis. Instead we sought to
review high-quality studies selected by preestablished criteria.
Studies were selected by searching Medline using the
following keywords: (1) quality of life; functional health;
(2) chronic kidney disease; chronic renal disease; end-stage
renal failure; end-stage renal disease; CKD; hemodialysis;
dialysis; predialysis; (3) erythropoietin; epoetin; hemoglobin
correction; (4) anemia; hemoglobin; haemoglobin; hemato-
crit. Using the above keywords and searching for articles
written in English and published between 1990 and 2007
resulted in 253 articles. Additional criteria (Figure 2) used to
select articles included the following: (1) articles must
have been randomized controlled trials (RCTs) or long-
itudinal clinical trials (LCTs) evaluating the effect of ESAs on
HRQOL in adult CKD patients; in the latter type of trial,
subjects were used as their own controls; (2) sample size must
have been greater than 30 subjects completing the study; (3)
subjects must have achieved a minimum increase in Hb of
1.5 g/100 ml or a minimum increase in hematocrit of 4.5%;
(4) investigators must have used a validated HRQOL
instrument and must have reported the actual data (not
simply whether the results were statistically significant or
not). With these additional criteria, 11 studies were selected
(Tables 2a–d).
SF-36
Although there is considerable variability among studies,
several patterns emerge. First, among the eight domains
measured by the SF-36, treatment of anemia appears to have
the most dramatic effects on vitality, whereas the effects on
bodily pain and emotional role are not clinically meaningful,
as they do not meet criteria for MCID. The remaining
five domains tested by the SF-36 show modest improve-
ments that meet criteria for MCID in some, but not all,
studies.
These results are consistent with the findings in the
‘Canada-Europe Study,’ one of the largest randomized clinical
trials to date evaluating the effects of anemia treatment in
Table 2a | Representative studies reporting an SF-36 score
DSF-36 subscales from baseline to end point
Author Trial Na
DHb (g/100 ml)
or Hct (%)b
General
health
Mental
health
Physical
function
Physical
role
Social
function Vitality
Bodily
pain
Emotional
role
Ritz et al. (ACORD)38 RCT 85 11.9-13.5 +5.33 NR NR NR NR NR NR NR
Singh et al. (CHOIR)2 RCT 715 10.1-12.6 +3.0 +1.7 +3.2 +6.4 +1.3 +10.0 +0.4 +0.8
Drueke et al. (CREATE)1c RCT 301 11.6-13.5 +4.1 +2.7 +3.4 +2.6 +1.8 +3.8 NR NR
Beusterien et al. (NCRHES)39 LCT 478 25.5-30.1 +1.9 +4.1 +3.7 NR +7.5 +9.3 +1.9 NR
CHOIR, Correction of Hemoglobin and Outcomes in Renal Insufficiency; CREATE, Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin-b; NCRHES, National
Cooperative Recombinant Human Erythropoietin Study; ACORD, Anemia Correction in Diabetes Study; CES, Canadian Erythropoietin Study Group; NR, not reported; RCT,
randomized controlled trial; LCT, longitudinal controlled trial; Hb, hemoglobin; SF-36, Short Form-36.
Scores meeting MCID criteria are in bold.
aN represents the number of subjects in the ESA-treated group (for RCTs) and the total number of subjects (for LCTs) who completed the study.
bChange in Hb or Hct from baseline to end of study. For those studies with two target hemoglobin groups, data from the ‘‘high’’ hemoglobin group are shown.
cSF-36 scores were estimated from the published figure.
Table 2b | Representative studies reporting a SIP score
DSIP subscales from baseline to end pointc
Author Trial Na
DHb (g/100 ml)
or Hct (%)b
Home
management
Alertness
behavior
Social
interaction
Physical
dimension
Psychosocial
dimension
Total (global)
score
Moreno et al. (SCRQOL)40 LCT 115 10.2-12.5 NR NR NR 1.3 2.2 1.65
Moreno et al.41 LCT 57 21-29 NR NR NR 5.8 8.2 6.3
Deniston et al.42d LCT 175 o8.5-10.6 9.0 5.0 6.0 2.0 6.0 5.0
CES43 RCT 33 7.1-11.7 NR NR NR 3.9 8.8 7.8
SCRQOL, Spanish Cooperative Renal Patients Quality of Life Study Group; CES, Canadian Erythropoietin Study Group; NR, not reported; RCT, randomized controlled trial; LCT,
longitudinal controlled trial; Hb, hemoglobin; SIP, Sickness Impact Profile.
Scores meeting MCID criteria are in bold.
aN represents the number of subjects in the ESA-treated group (for RCTs) and the total number of subjects (for LCTs) who completed the study.
bChange in Hb or Hct from baseline to end of study. For those studies with two target hemoglobin groups, data from the ‘‘high’’ hemoglobin group are shown.
cHigher scores on the SIP indicate poorer health. Consequently, negative changes in the subscales indicate improvements in health.
dBaseline SIP scores were not reported. Therefore, scores represent differences between the ESA-treated versus nontreated groups (mean Hb of nontreated group was
8.3 g/100 ml).
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CKD patients.47 In this study of 596 patients, Hb was
corrected to 13.3 and 10.9 g/100 ml in the two treatment
groups. After 24 weeks of treatment, SF-36 vitality scores
were 4.1 points higher (meeting MCID criteria) in the high as
compared to low-target Hb group. Similarly, in an even larger
and more recent randomized study known as the Correction
of Hemoglobin and Outcomes in Renal Insufficiency
(CHOIR) trial, improvement in the SF-36 vitality score
following Hb correction from 10.1 (at baseline) to 11.3 g/
100 ml (in the low-Hb group) was 8.2 units.2 This
improvement is approximately twice the MCID and dwarfs
improvements found in other SF-36 HRQOL domains.
However, in the CHOIR trial the low-Hb group (11.3 g/
100 ml) showed improvements similar in magnitude to those
of the high-Hb group (12.6 g/100 ml) in all SF-36 domains
except for emotional role. In this latter domain, the lower-Hb
group in fact outperformed the high-Hb group (mean change
from baseline þ 5.9 versus þ 0.8 units, respectively).
Although the CHOIR trial found no HRQOL benefits in
the high- versus low-Hb group, the investigators have been
criticized for reporting only the ‘KDQ total score’ without
mentioning the five distinct subscales that encompass the
questionnaire.48
Improvement in the SF-36 vitality subscale following
treatment of anemia is consistent with studies of peak oxygen
consumption (VO2) and exercise performance. McMahon
et al.49 found that targeting an Hb of 14 compared to 10 g/
100 ml in hemodialysis patients was associated with an 18%
increase in peak VO2. These increases were demonstrated in
younger and older patients alike. Similarly, numerous studies
have shown substantial improvements in exercise perfor-
mance following only partial correction of anemia.50–53
The clinical importance of a 10-point increase in the SF-36
vitality score might not be immediately obvious. The vitality
score, as described above, is a composite of four questions
asking about fatigue and energy. As an example, a 10-point
increase in vitality score could be achieved by answering the
question, ‘did you have a lot of energy during the last 4
weeks?’ with the response ‘none of the time,’ versus ‘some of
the time.’ Similarly, answering the question with ‘some of the
time’ versus ‘most of the time’ would also yield a 10-point
difference in score.
SIP and LASA
Despite a paucity of reports, both SIP and LASA scales show
clinically significant improvement with increasing Hb levels
in most, but not all, studies. Interestingly, treatment of
anemia appears to have a greater effect on the psychosocial
dimension of the SIP scale as compared to the physical
dimension. This pattern stands in contrast to the SF-36, in
which Hb changes exert a greater impact on physical and
energy-related domains than social, mental, and emotional
domains. In addition, the two studies42,54 that reported SIP
subscales demonstrated clinically meaningful improvements
in home management, alertness behavior, and social inter-
action. The home management scale measures an individual’s
ability to carry out everyday activities, such as housework
and shopping, whereas the alertness behavior scale evaluates
subjective changes in memory, judgment, and cognitive
behavior.
KDQ
Studies that have used the KDQ to evaluate HRQOL have
shown that the greatest improvements (threefold greater than
Table 2c | Representative studies reporting a LASA score
DLASA subscales from baseline to end point
Author Trial Na DHb (g/100 ml)b Energy Activity Overall quality of life
Singh et al. (CHOIR)2 RCT 715 10.1-12.6 +16.6 +15.0 +11.2
Provenzano et al.44 LCT 1,338 9.1-11.6 +27.9 +24.5 +22.6
CHOIR, Correction of Hemoglobin and Outcomes in Renal Insufficiency; RCT, randomized controlled trial; LCT, longitudinal controlled trial; Hb, hemoglobin; LASA, Linear
Analog Self-Assessment.
Scores meeting MCID criteria are in bold.
aN represents the number of subjects in the ESA-treated group (for RCTs) and the total number of subjects (for LCTs) who completed the study.
bChange in Hb from baseline to end of study. For those studies with two target hemoglobin groups, data from the ‘‘high’’ hemoglobin group are shown.
Table 2d | Representative studies reporting a KDQ score
DKDQ subscales from baseline to end point
Author Trial Na DHb (g/100 ml)b Physical symptoms Fatigue Depression Relationships Frustration Overall
Provenzano et al.44 LCT 1338 9.1-11.6 +1.5 +1.4 +0.8 +0.8 +0.8 +5.4
Furuland et al.45 RCT 129 10.9-13.6 +0.66 +0.16 0.00 0.00 0.00 +0.82
Foley et al.46 RCT 49 10.1-12.8 +1.1 +0.25 +0.05 0.07 0.07 +1.26
CES43 RCT 33 7.1-11.7 +1.4 +1.1 +0.7 +0.6 +0.4 +4.2
CES, Canadian Erythropoietin Study Group; NR, not reported; RCT, randomized controlled trial; LCT, longitudinal controlled trial; Hb, hemoglobin; KDQ, Kidney Disease
Questionnaire.
Scores meeting MCID criteria are in bold.
aN represents the number of subjects in the ESA-treated group (for RCTs) and the total number of subjects (for LCTs) who completed the study.
bChange in Hb from baseline to end of study. For those studies with two target hemoglobin groups, data from the ‘‘high’’ hemoglobin group are shown.
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the MCID, in some studies) associated with treatment of
anemia occur in the domains of physical symptoms and
fatigue, whereas the remaining three domains (depression,
relationships, and frustration) show improvements that meet
MCID criteria only in a minority of studies. These findings
are similar to the results of a meta-analysis of anemia
treatment, in which it was found that the effect size of
erythropoietin on various HRQOL domains was largest
(1.07) for performance score, a method of quantifying the
functional status of chronically ill patients.11 To put the KDQ
score into perspective, a change of one point (twice the
MCID) in the KDQ subscale of fatigue could be achieved by
answering the question, ‘how often during the past 2 weeks
have you felt weak?’ with the response ‘all of the time,’ versus
‘none of the time’.
The two studies in Table 2d in which improvements in
KDQ scores are markedly attenuated are the same in which
there is a higher baseline Hb concentration.46,45 We therefore
investigated the possibility that the patients in Foley and
Furuland’s studies may have been healthier at baseline, and,
consequently, less likely to manifest substantial improve-
ments in KDQ scores as compared with their sicker, more
anemic, counterparts in the other two studies. The baseline
KDQ scores of the patients in Foley and Furuland’s studies
were indeed universally higher (indicating better baseline
health) on all subscales as compared with the baseline scores
of the remaining two studies.
Improvements in HRQOL with incremental increases in Hb
The possibility that ESA-associated improvements in
HRQOL may depend, in part, on baseline Hb concentration,
and that such improvements may have a ‘ceiling effect’
beyond which further treatment of anemia fails to improve
HRQOL has been investigated.55 Using data from the
POWER study,44 Lefebvre examined the relationship between
LASA and KDQ scales and incremental increases in Hb
concentration among 1,338 CKD patients. The results
(Figure 3) show a sigmoid-shaped curve, similar to prior
analyses of anemic cancer patients receiving chemo-
therapy.56,57 As demonstrated in Figure 3, the maximal gain in
quality of life occurred between Hb values of 10–12 g/100 ml.
Beyond those levels, additional increases in Hb continued to
improve HRQOL, albeit at a much reduced rate. Signifi-
cantly, the study was a post hoc analysis and therefore could
have been confounded by patients who were hyporesponsive
to ESAs due to an underlying condition. Such patients would
be expected to have poorer HRQOL irrespective of their Hb
values. Lefebvre attempted to minimize any such bias by
analyzing the data longitudinally, however, a confounding
effect may have nonetheless persisted.
The finding that HRQOL continues to improve following
correction of even mild anemia is consistent with the findings
of the US Normal Hematocrit Study.58 In this study, 1,233
hemodialysis patients with cardiac disease were randomized
to a hematocrit of 30 versus 42%. At 12 months, an increase
in the SF-36 physical-function score of 0.6 was noted for each
percentage-point increase in the hematocrit in the range of
30–42%. By extrapolation, an increase in Hb from 12 to 14 g/
100 ml (corresponding roughly to an increase in the
hematocrit by 6%) would result in an increase in the SF-36
physical-function score of 3.6. Such an improvement would
meet criteria for a clinically important effect, although by a
very small margin (MCID for the SF-36 is approximately 3–5
units).
Although such curves as shown in Figure 3 are helpful in
defining the relationship between correction of anemia and
improvements in HRQOL, not all studies have documented
such a relationship. The investigators in the CHOIR trial
found similar HRQOL improvements (measured by the
SF-36, LASA, and KDQ) in their high- and low-target Hb
groups.2 Likewise, although Foley and colleagues found
improvements in some KDQ subscales in their higher Hb
group, they found no significant changes in any of the SF-36
dimensions.46 Similarly, Roger et al.59 were unable to
demonstrate a difference in HRQOL (measured by the
SF-36 and the Renal Quality of Life Profile) between their
two treatment groups. However, they attributed this negative
finding to the small overall difference in Hb concentration
between groups (12.2 versus 11.0 g/100 ml).
Keyword search
253 articles
Did not assess ESAs and/or HRQOL
Not RCT or LCT
N<30
Hb Increase <1.5 g/100 ml
Use of nonvalidated instruments
Failure to report data
11 articles selected
77 excluded 
142 excluded 
18 excluded 
1 excluded 
2 excluded 
2 excluded 
Figure 2 | Flow diagram showing selection of articles. Articles
were found by keyword search and excluded based on
preestablished criteria (described above). HRQOL, health-related
quality of life; RCT, randomized controlled trial; LCT, longitudinal
clinical trial; Hb, hemoglobin.
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Additional HRQOL domains
Correction of anemia is likely to result in HRQOL benefits
across multiple domains, including some that are not
measured directly by the commonly used instruments
described above. These additional domains include sleep
adequacy, cognitive functioning, and sexual functioning.
Discussion of these alternative HRQOL domains is limited by
small sample sizes and the fact that MCIDs have not been
firmly established. We have therefore reviewed studies here
that would not have qualified for inclusion in the primary
analysis based on the criteria above.
To assess the effect of Hb normalization on sleep patterns
and sleep quality, Benz et al.60 used polysomnography to
measure the number of periodic limb movements in sleep in
10 dialysis patients in the SLEEPO study. Benz found that
correction of anemia from a hematocrit of 32.3–42.3%
resulted in a highly significant reduction (54.1%) in the
number of arousing periodic limb movements in sleep
episodes. In addition, subjects were able to remain awake in a
dark quiet room for significantly longer periods of time (9.7
versus 17.1 min) after correction of anemia. Previous research
has also documented substantial improvements in subjective
quality of sleep following correction of anemia in CKD
patients.42 Although MCIDs have not been established for the
above instruments used to assess sleep adequacy, the MCID
approximation proposed by Norman32 (one half a standard
deviation) is indeed achieved in Benz’s study, suggesting that
the findings are clinically relevant.
Partial correction of anemia (from hematocrit 22.7 to
30.6%) was shown by Grimm et al.61 to result in improve-
ment of brain functioning as assessed by P300 event-related
potentials and by the Trail-Making Test. The former is an
electrophysiological measurement reflecting internal mental
events involving such processes as stimulus recognition and
decision-making, whereas the latter is a neurocognitive
instrument predominantly testing the domains of processing
speed, sequencing, mental flexibility, and visual–motor
skills.62 Pickett et al.63 showed that full normalization of
Hb resulted in additional cognitive benefits in 20 CKD
patients, as compared with only partial correction.
In the National Cooperative Recombinant Human Ery-
thropoietin Study, correcting the hematocrit from 25.5 to
30.1% in 484 CKD patients led the proportion of subjects
reporting that they were ‘very satisfied’ with their sexual
relationships to increase significantly from 3% at baseline to
8% at follow-up.39 The proportion reporting that they were
‘dissatisfied’ decreased from 12% at baseline to 7% at follow-
up. Other studies have also documented significant improve-
ments in sexual functioning among CKD patients treated
with ESAs.64,65
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Figure 3 | Hemoglobin levels (g/100 ml) and associated KDQ scores for physical symptoms, fatigue, depression, relationship with
others, frustration, and overall KDQ. Similar curves (not shown) were generated for LASA scales in the domains of activity, energy, and
overall quality of life. Figure reproduced with permission from Lefebvre et al.55
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DISCUSSION
The main conclusions of this review are: (1) correction of
anemia in CKD results in clinically relevant improvement in
HRQOL; (2) HRQOL domains that are most improved relate
to physical symptoms, vitality, energy, and performance; (3)
domains of social functioning and mental health show
modest improvement, whereas the domains of emotional
functioning and pain show very little improvement; (4)
commonly used instruments, such as the SF-36, may
inadequately capture the true impact of Hb normalization
on HRQOL by not measuring all relevant domains, such as
sleep, cognitive functioning, and sexual functioning, all of
which have been documented to improve with erythropoie-
tin; (5) the maximal increase in HRQOL per incremental
increase in Hb appears to occur in the range of 10–12 g/
100 ml. Beyond this range, additional normalization of Hb
(12–14 g/100 ml) appears to result in continued (albeit
blunted) improvements in HRQOL. However, a paucity of
studies evaluating HRQOL among subjects with Hb values in
this upper range makes it difficult to draw firm conclusions.
Perils and confounders
There are several perils and confounders in the interpretation
of HRQOL data. Statistically significant improvements in
HRQOL instruments may not translate into clinically mean-
ingful effects, especially when multiple subscales are used.
Thus, the probability of finding statistical significance due to
chance alone (type I error) is increased. Utilizing an MCID
approach or, alternatively, a distribution-based approach,
although not without limitations, can help clinicians and
researchers interpret the clinical relevance of changes in
HRQOL instruments. Once HRQOL data are reported as the
proportion of patients whose improvements meet criteria for
an MCID, the number of patients that need to be treated
(NNT) for one patient to benefit can be readily calculated
and used by both clinicians and policy-makers.28
A potential confounder of HRQOL studies is patient
knowledge of the intervention.11 Most studies of Hb normal-
ization fail to state whether the subjects were blinded to their
Hb concentration when they completed their HRQOL
assessments. Investigators have suggested that Hb values should
be withheld from patients participating in ESA-associated
HRQOL trials.66 However, even with adequate blinding,
patients may still sense that they are receiving erythropoietin
in higher or more frequent doses. In a study of 1,007 cancer
patients receiving erythropoietin, knowledge of Hb level was
associated with HRQOL score on 5 of 11 scales studied.67
However, because the magnitude of the association was modest
(often below the MCID) it was unlikely to explain large group
differences in HRQOL. Furthermore, only 23.2% of the
patients reported knowing their Hb level and, of those, the
reported value was inaccurate (defined as more than 1 g/100 ml
different than the measured Hb) in 12% of patients.
Nonetheless, there exists a reasonable possibility that patient
knowledge of Hb may confound HRQOL data, and this
potential bias should be avoided whenever possible.
Another potential confounder of HRQOL studies is bias
from the mode of survey administration. Although most
studies discussed above used self-administered question-
naires, Unruh et al.68 examined the relationship between
self-administered versus interviewer-administered surveys of
HRQOL in the HEMO study. After adjustment for baseline
differences in health, patients in the interviewer-administered
group reported higher scores on several HRQOL domains.
This bias may stem from patients’ desires to present
themselves in a more favorable light when confronted with
an interviewer. Accordingly, any study of HRQOL that
utilizes multiple modes of survey administration should take
such differences into account.
Limitations
Documents from a recent FDA Advisory Committee discuss
multiple limitations of many HRQOL studies: open-label
design, post hoc selection of items and subscales, lack of
power to detect changes in HRQOL, and the use of
unvalidated instruments.69,70 Although many of these criti-
cisms are well founded, the latter limitation has been
discussed above. In brief, commonly used HRQOL instru-
ments, although not validated specifically in CKD patients,
have shown a remarkable convergence of results across
different disease groups.
Cost-effectiveness
Economic considerations will ultimately play a large role in
determining Hb targets. One study evaluating the cost-
effectiveness of erythropoietin in hemodialysis patients found
that the cost per quality-adjusted life year (QALY) gained by
a target Hb of 11.0–12.0 g/100 ml (compared to 9.5–10.5 g/
100 ml) was $55,295, a value that might be considered
reasonable.71 As progressively higher Hb targets were
considered, the incremental cost per QALY gained rose
considerably ($613,015 more per QALY for a target Hb of
12.0–12.5 g/100 ml compared to 11.0–12.0 g/100 ml; $828,215
more per QALY for a target Hb of 14.0 g/100 ml compared to
12.0–12.5 g/100 ml) as the increases in QALY gained were
small. The authors concluded that any potential offsetting of
these costs by decreased hospitalization rates would be
unlikely to bring the adjusted cost below a marginally
acceptable cost-effectiveness ratio of o$100,000 per QALY.
Consequently, Hb targets in excess of 12 g/100 ml were
considered unfavorable from a cost-effectiveness perspective.
In arriving at this conclusion the authors assumed that the
majority of improvement in HRQOL occurs in the Hb range
of 11–12 g/100 ml, with additional improvements in HRQOL
being blunted at higher values. Given the findings of previous
HRQOL studies (discussed above), this assumption seems
reasonable. Other assumptions made by the authors were
conservative in that they favored the higher Hb targets,
further strengthening their findings.
We must note that the value of improvements in HRQOL
attributable to treating anemia are not easily assessed if life
expectancy is curtailed as the result of the same intervention.
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The CHOIR and CREATE trials leave uncertainty regarding
the optimal Hb concentration in CKD patients. The
improvements in HRQOL we review here occurred at Hb
concentrations that partly overlap with that of the higher Hb
groups in those RCTs of treatment of anemia. If higher
mortality rates result from higher Hb concentrations as
occurred in CHOIR2, or more patients with higher Hb
concentrations than lower required initiation of dialysis as
occurred in CREATE1, the relative merits of the improve-
ments in HRQOL that occur as Hb rises are difficult to
calculate. Patients may make individual judgments regarding
the relative importance of quality of life versus life
expectancy.
In summary, many studies have evaluated the effects of
anemia correction on the quality of life of CKD patients.
Although patterns can be identified, there exists marked
heterogeneity in the reported findings. The lack of uniformity
in the findings can be explained by a variety of demographic
and methodological differences, including differences in
baseline health status, instruments, and Hb targets. Emerging
from future studies will likely be the conclusion that there is
no single ideal target Hb for all CKD patients, but rather that
such targets will and should be tailored to the individual
patient based on a multitude of underlying factors. These
factors should include, but not be limited to, the patients’
baseline quality of life, goals for improvement, and
underlying medical and specifically cardiovascular comor-
bidities.
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